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Abstract: The human gastrointestinal tract is inhabited by trillions of commensal bacteria collectively
known as the gut microbiota. Our recognition of the significance of the complex interaction between
the microbiota, and its host has grown dramatically over the past years. A balanced microbial
community is a key regulator of the immune response, and metabolism of dietary components,
which in turn, modulates several brain processes impacting mood and behavior. Consequently, it is
likely that disruptions within the composition of the microbiota would remotely affect the mental
state of the host. Here, we discuss how intestinal bacteria and their metabolites can orchestrate
gut-associated neuroimmune mechanisms that influence mood and behavior leading to depression.
In particular, we focus on microbiota-triggered gut inflammation and its implications in shifting the
tryptophan metabolism towards kynurenine biosynthesis while disrupting the serotonergic signaling.
We further investigate the gaps to be bridged in this exciting field of research in order to clarify our
understanding of the multifaceted crosstalk in the microbiota–gut–brain interphase, bringing about
novel, microbiota-targeted therapeutics for mental illnesses.
Keywords: microbiota; kynurenine pathway; serotonin; inflammation; gut motility
1. Introduction
The complex communities of the microbiota that inhabit the mammalian gut have a significant
impact on the health of their host. These gut bacteria has coevolved with the human body to perform
numerous beneficial functions ranging from being simple fermenters of food to having profound
effects on the host immune development, metabolism and food preferences, brain development,
stress responses, pain, and behavior [1–5]. Consequently, disruptions or alterations in this resilient
relationship are a significant factor in many diseases such as inflammatory gastrointestinal diseases
and neuropsychiatric disorders, including depression [1,6–8].
Depression is a severe neuropsychiatric disease with multiple comorbidities in play. According to
the World Health Organization (WHO), this longstanding mental disorder affects more than 300 million
people of all ages worldwide [9]. Moreover, it is the leading cause of disability in modern society,
and approximately one million people suffering from depression commit suicide every year [9].
It is widely recognized now that depression is closely linked with inflammation, and disrupted
serotonergic systems throughout the human body, including the gut [10–16]. In fact, in a state of
inflammation, not only high levels of proinflammatory cytokines are produced but also altered levels
of neurotransmitters, such as serotonin, a derivative of tryptophan metabolism, are detected in the
gut [17–19]. The presence of vast majority of bodily serotonin and immune cells in the gut in close
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proximity to the trillion of the gut-associated microbes implies the gut microbiota is likely to be an
orchestrator in this multifaceted crosstalk between inflammation, serotonin, and depression, as will be
discussed in this review article.
2. Gastrointestinal Inflammation and Depression
In a state of intestinal inflammation, the immune system responds by producing various
proinflammatory cytokines and metabolites, several of which are detected in the systemic blood
circulation [20]. The fact that these molecules can cross the blood–brain barrier suggests that they
can signal to the brain to ultimately result in serious changes in behavior [21]. Several routes,
by which cytokines and metabolites present in the gut can influence the brain and behavior, have
been described; (1) neural, (2) humoral, (3) cellular, and (4) carrier route [22] (Figure 1A). In the
neural route, afferent nerves, such as the vagus nerve, are involved. Vagal nerves are activated by
proinflammatory cytokines and other metabolites released by immune cells, neurons or intestinal
bacteria during intestinal inflammation or infections [23] (Figure 1Aa). This cascade leads to activation
of the hypothalamus–pituitary–adrenal axis, thus increased levels of cortisol (stress hormone) and
decreased levels of brain-derived neurotrophic factor [21]. The humoral route involves signaling via the
circumventricular organs (CVOs), which have been described as a way by which leukocytes can reach
the central nervous system [24]. CVOs are areas in the brain that lack an intact blood–brain barrier,
thus allow molecules with limited access to the brain to migrate [25] (Figure 1Ab). The carrier route
includes cytokine transporters at the blood–brain barrier, where circulating cytokines can access the
brain via the energy- and carrier-dependent active transport system or via no energy-dependent
carrier-mediated facilitated diffusion system, commonly called saturable transport systems [26]
(Figure 1Ac). Finally, the cellular route involves cytokine receptors, such as receptors for tumor necrosis
factorα (TNF-α) and interleukin (IL)-1β, expressed on non-neuronal cells in the brain, such as microglia
and astrocytes [27–29]. Binding of TNF-α and IL-1β to their receptors in the brain activates cerebral
NF-κB signaling pathway and induces the production of secondary cytokines, which can promote
a depressed mood [29,30] (Figure 1Ad). Indeed, proinflammatory cytokines, such as interferon-γ
(IFN-γ), IL-2, TNF-α, and inflammatory markers such as C reactive protein (CRP), have been linked
to higher risk of depression [31,32]. All together, these pathways show a number of sophisticated
signaling mechanisms in the brain, which when stimulated by molecules produced during intestinal
inflammation could lead to altered brain functionality, potentially leading to progression of depression.
2.1. A Gut Perspective on the Role of Tryptophan Metabolites in Depression
Tryptophan is an essential amino acid, derived from the diet [33]. Apart from its role in protein
synthesis, tryptophan and its metabolites are associated with numerous physiological functions,
such as immune homeostasis, but also with inflammatory response [34]. Once absorbed in the gut,
tryptophan can cross the blood–brain barrier to participate in serotonin synthesis [35]. However,
there are many other pathways through which tryptophan can be readily metabolized in the gut,
thereby influencing its availability to pass the blood–brain barrier. Among these pathways are the
kynurenine [36] and the serotonin synthesis pathways within the gut [37,38]. Kynurenine and serotonin
are vital signaling molecules in immune response and gut–brain communication [34,39,40]. Most of
the digested tryptophan (about 90%) is metabolized along the kynurenine biosynthesis pathways [41],
while only approximately 3% is metabolized into serotonin throughout the body, and the rest is
degraded by the gut microbiota to produce indole and its derivatives [42]. This implies a strong
competition between serotonin and the first downstream metabolites from the kynurenine pathway,
kynurenine, for the available tryptophan, as described below. In inflammatory conditions, more
kynurenine is produced on the expenses of serotonin [43,44], which, if happens also in the brain,
results in behavioral changes including persistent sadness, loss of interest, and decreased energy
levels [45] (Figure 1A).
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2.2. Gut Inflammation-Induced Kynurenine Biosynthesis; Possible Cause of Altered Kynurenine Pathway in the
Brain during Depression?
Tryptophan forms kynurenine via the rate-limiting enzyme, indoleamine-2,3-dioxygenase (IDO)
enzyme, found ubiquitously in all tissues, including the gut, and tryptophan-2,3-dioxygenase (TDO),
which is localized in the liver [41]. The activity of TDO and IDO is uniquely induced by different
stimuli; while TDO is induced by stress-elevated glucocorticoids, such as cortisol [46], IDO is induced
during intestinal inflammation [47] by proinflammatory stimuli, with interferon γ (IFN-γ) being the
most potent inducer [48]. Induction of IDO results in a shift in the tryptophan metabolism towards
the production of kynurenine and its downstream metabolites; kynurenic acid, anthranilic acid,
and quinolinic acid rather than serotonin synthesis [47,49] (Figure 1A,B). Moreover, activated IDO
accelerates the degradation of serotonin into formyl-5-hydroxykynuramine [50,51]. Degradation of
serotonin yields reactive oxygen species byproducts and subsequently inflammation [52]. This further
intensifies serotonin deficiency, leading to the disruption in neurotransmission and consequently
causes depression.
In contrast to kynurenic acid and quinolinic acid, kynurenine and anthranilic acid can cross
the blood–brain barrier via the saturable transfer [53]. This suggests that inflammatory-induced
altered levels of kynurenine in the gut may transfer to the blood circulation and ultimately to the
brain, resulting in altered levels of kynurenine and its metabolites, kynurenic acid, and quinolinic
acid (Figure 1A). In fact, during inflammation, the enzymes of the kynurenine pathway are activated
leading to changed production of kynurenic and quinolinic acids. Depression is believed to arise from
the excessive production of the neurotoxic quinolinic acid together with a reduction in kynurenic
acid [54]. Reduced levels of kynurenic acid have been correlated with severe depressive and suicidal
symptoms [55,56], and decreased blood levels of this molecule has been detected in the patients
with major depressive disorder [57]. Quinolinic acid is a neurotoxic agent, and its production is
significantly enhanced by proinflammatory cytokines through their stimulation of the rate limiting
step enzyme in the quinolinic acid pathway, kynurenine-3-monooxygenase (KMO) enzyme [58,59].
For instance, levels of quinolinic acid in the cerebrospinal fluids of suicide attempters showed around
300% increase compared to healthy controls [60]. In the brain, quinolinic acid acts as an agonist
of N-methyl-D-aspartate (NMDA) receptors, which play a key role in the regulation of synaptic
function [61]. Activation of NMDA receptors upon binding to quinolinic acid has been described
to be another mechanism involved in promotion of depression [49]. Specifically, when microglia
are stimulated by proinflammatory cytokines, glutamate, another agonist of NMDA receptors,
and the main excitatory neurotransmitter in the central nervous system, is released leading to
additional activation of NMDA receptors [61]. Therefore, quinolinic acid alone or in combination
with glutamate, can enhance NMDA receptor activation and subsequently lead to depression [49].
Intriguingly, a high proportion of the enteric neurons in the gut express the NMDA-type glutamate
receptors [62,63]. In line with these observations, previous data have suggested that enhanced
activation of NMDA receptors maybe involved in altered inflammation-linked motility and in
inflammatory-induced nociception [64,65] as a remote consequence of intestinal inflammation on
the brain [66] (Figure 1B). In contrast to quinolinic acid, kynurenic acid is an indigenous antagonist of
the enteric NMDA receptors, thereby suppressing the hypermobility of the gut associated with the
activated NMDA receptors and excitability of the enteric neurons during an intestinal inflammatory
response. Collectively, the current data support an effect of intestinal inflammation on redirecting the
tryptophan metabolic pathway towards kynurenine rather that serotonin biosynthesis. Kynurenine
metabolites have a profound effect on the enteric nervous system and intestinal motility alteration.
Whether altered gut motility can stimulate a state of depression and whether changes in intestinal
kynurenine metabolism could be the source of altered levels of these metabolites in the brain, warrant
more investigation.
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2.3. Intestinal Inflammation and Disrupted Serotonin Signaling System: From Alterated Gut Functionality to
Development of Depression
Serotonin is a key-signaling regulator that modulates a wide range of effects on host physiology,
including the control of gut motility, secretory reflexes, platelet aggregation, regulation of immune
responses, and regulation of mood and behavior [67]. Once tryptophan is absorbed in the gut, it crosses
the blood–brain barrier to be partially metabolized into serotonin in the raphe nuclei within the brain
stem [34]. However, the majority (~95%) of serotonin in the body is synthesized, stored, and released
in the gut, mainly from a subset of enteroendocrine cells called enterochromaffin cells in the intestinal
mucosa [19]. The small amount of serotonin that is not in enterochromaffin cells is in the enteric nervous
system, in particular, the myenteric plexus, which contains descending serotonergic interneurons [68]
(Figure 1B).
Enterochromaffin cells, also known as epithelial sensory transducers, secrete serotonin in response
to mucosal stimuli, such as microbiota metabolites as discussed below. Once synthesized, serotonin is
secreted in the lamina propria, where it has access to the nerve fibers. This implies a large amount
of serotonin is secreted in the extracellular space. Thus, to avoid receptors’ desensitization by their
contact with excessive amounts of serotonin, which is toxic [69], serotonin overflow must be efficiently
controlled. One important player in serotonin uptake by gut epithelial cells, thus serotonergic
termination, is the Na+/Cl− dependent, serotonin transporter (SERT). SERT, is a recently crystallized
protein [70] comprised of 12 transmembrane domains, and is a member of a large superfamily of
sodium/chloride dependent transporters, which also contain transporters for other neurotransmitters,
such as dopamine and norepinephrine [71].
Secreted serotonin mediates its actions via several receptor subtypes [72], where it has been
observed to affect epithelial cells’ proliferation and secretion [73], but mainly acts as a regulator of the
gut motility. Secretion of serotonin by enterochromaffin cells activates intrinsic primary afferent neurons
(IPANs) in the submucosal plexus via its action on 5-HT1P receptor. These cells initiate peristaltic and
secretory reflexes, which influences gut motility (Figure 1C). Moreover, intestinal serotonin activates
extrinsic sensory nerves via its action on 5-HT3, which are postsynaptic receptors found on the terminals
of extrinsic sensory neurons terminal in the gut and transmit noxious signals to the brain [74] (Figure 1B).
Though it does not initiate peristaltic movement, 5-HT3 conveys any kind of change in gut motility
to the brain via its presence on myenteric IPANs and in the myenteric plexus, where they mediate
fast excitatory neurotransmission [75]. Similarly, 5-HT4 receptors themselves do not initiate peristaltic
reflexes, but because of their location at the terminals of submucosal IPANs, at synapses within the
myenteric plexus, and at the neuromuscular junction, stimulation of 5-HT4 receptors is critical for
these reflexes [76]. 5-HT4 receptors work through stimulating the production of the neurotransmitters
acetylcholine and calcitonin gene-related peptide, which enhances the spread of stimuli around and
through the gut wall, to ultimately enhance and maintain a normal gut motility [77,78].
The strong link between inflammation, and disruptions of serotonin metabolism has been well
established. Immune cells including lymphocytes, mast cells, dendritic cells and monocytes have
all been reported to express SERT, serotonin receptors and enzymes involved in the production and
metabolism of serotonin [79,80] (Figure 1C). T lymphocytes express the main components of serotonin
metabolism, i.e., tryptophan hydroxylase (TPH), the first rate limiting enzyme involved in serotonin
production, SERT, monoamine oxidase (MAO) [80], which breaks down serotonin into its metabolite
5-HIAA, and 5-HT receptors [80]. While resting, naïve T cells express very little TPH1, the TPH
isoform present in the intestinal enterochromaffin cells, where intestinal serotonin is synthesized,
activated T cells show approximately 30-fold higher expression of TPH1, suggesting increased levels
of serotonin in activated T cells [81], and 5-HT receptors, including 5-HT1B, 5-HT2A, and 5-HT7
receptors [81]. However, expression of SERT in T cells is still questionable; León-Ponte et al. shows
that neither naïve nor activated T cells express high-affinity SERT [81], however another study claims
that SERT is present in T cells membranes [82] (Figure 1C). Thus, these contradictory conclusions
warrant further investigation. B lymphocytes are also known to express 5-HT receptors, including
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5-HT1A, 5-HT2A, 5-HT3A and 5-HT7 [80], and activated B cells exhibit a significant increase in SERT
expression [83] (Figure 1C). Whether B cells express other components of serotonin machinery and
thus influencing serotonin signaling, it is still unknown. Like T cells, monocytes, the immature
leukocytes that eventually differentiate into macrophages or dendritic cells, express the complete
set of components needed for serotonin production [80]. Dendritic cells, have also been found to
mediate the release of proinflammatory cytokines, IL-1β and IL-8 via 5-HT3, 5-HT4, and 5-HT7
receptor subtypes [84]. In fact, serotonin has been demonstrated as an important regulator of the
immune system. For example, serotonin has been described to modulate proinflammatory cytokines
production in human monocytes via stimulation of different 5-HT receptor subtypes, particularly
5-HT3, 5-HT4, and 5-HT7 receptors [85] (Figure 1C). Interestingly, deletion of 5-HT4 receptors in
mice results in inflammatory response, slowed colonic motility, and behavioral abnormalities [86,87].
Similarly, reduced expression of SERT and subsequent altered serotonin levels, have been associated
with different inflammatory and diarrheal disorders [15,16,88]. Targeted deletion of the SERT in
mice led to increased colonic motility and increased water in stools [89] in a similar manner to that
observed in inflammatory bowel disorders, where SERT expression is also reduced [18,90]. That the
altered structure or expression of SERT leads to disrupted serotonin transmission [91], the current
data point to a strong link between intestinal inflammation, disruption of serotonin signaling and
the consequent alteration in gut motility, and development of depression. Whether the altered gut
motility [14,16,88,89,92,93] is the driving factor in inducting depression in this cascade is unclear.
One plausible mechanism is via the gut motility-mediated changes in the microbial population
complexity, which might exert detrimental effects on enteric and central neurons leading to a state
of depression.
3. Microbiota as an Orchestrator in the Crosstalk between Inflammation and Serotonin Imbalances
The presence of vast number of gut microbiota in close proximity to serotonin and immune cells
in the gut, makes it plausible to consider these bacteria as a conductor in the orchestra of intestinal
inflammation and serotonin, to remotely result in a state of altered mood and depression in the brain
(Figure 1).
3.1. Gut Microbiota and Intestinal Immune (Hyper)-Stimulation
It is well-established that the gut microbiota plays a critical role in both innate and adaptive
immunity, where it mediates the formation, maturation, and function of several immune cells [94].
Interactions between the gut bacteria and gut mucosa regulate the production of numerous
proinflammatory cytokines [95–97]. Several species within the gut bacteria have been shown to be
essential in the development and maturation of the immune response. For example, a monocolonization
of germ-free mice with the ubiquitous gut bacterium, Bacteroides fragilis, shows immunomodulatory
activities of this bacterium, including correction of T cell deficiencies and TH1/TH2 imbalances [98].
Segmented filamentous bacteria, the epithelial-associated bacteria, stimulate the maturation of
proinflammatory IL-17A-producing T helper 17 (TH17) cells in the mouse small intestine [99,100].
Though considered as commensals, these bacteria have pathogenic properties and are referred
to as pathobionts due to their capacity to induce a profound inflammatory state if an imbalance
within the microbial population (also known as dysbiosis) occurs [101]. Microbial dysbiosis has
been strongly linked to inflammatory bowel disease, a comorbidity of anxiety and depression [102].
Increased relative abundance of Escherichia coli and Enterococcus faecalis have been described to induce
intestinal inflammation and bacterial-antigen specific cytokine production (IFN-γ and IL-4) in a
well-characterized murine colitis model IL10−/− [103]. Several Bacteroides genera have been recognized
to be important for induction of inflammatory bowel disease in IL-10r2−/− × Tgfbr2−/− mouse colitis
model [104]. Klebsiella pneumoniae and Proteus mirabilis, has been positively correlated with colitis
in Tbx21−/− × Rag2−/− mouse inflammatory bowel disease model [105]. A common resident of the
human mouth and gut, Fusobacterium nucleatum, when isolated from the inflamed gut of Crohn’s
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disease patients evoked significantly greater TNF-α gene expression [106]. Finally, in experimental
autoimmune encephalomyelitis, a mouse model of multiple sclerosis, germ-free or antibiotic-treated
mice exhibited reduced inflammation and disease scores compared to conventional mice, suggesting
a role for gut microbes on peripheral immune response, leading to brain inflammation [107,108].
Overall, these data suggest gut microbiota as an important immunomodulatory player in the
gut–inflammation–brain crosstalk (Figure 1D).
3.2. Gut Microbiota and Serotonin Production
Recently, it has been shown that gut microbiota plays an important role in the regulation of
the host serotonin levels [109]. Particular microbial metabolites, namely short chain fatty acids,
have been shown to promote serotonin production from enterochromaffin cells in the epithelia
via induction of TPH1 gene expression [109,110] (Figure 1D), most likely, due to their acidic pH.
The effect of gut microbiota on intestinal serotonin levels expands beyond the gut. Plasma serotonin
levels were in germ-free mice compared to conventional mice [111]. On the other hand, levels
of hippocampal serotonin were significantly increased in germ-free and colonized germ-free mice
compared to conventional mice [112]. However, a causation of differences in serotonin levels in
germ-free mice still needs to be explained. Yano et al., further showed that SERT expression is
increased in germ-free mice, suggesting its regulation by gut microbiota [109]. Indeed, SERT genotype
has been linked to altered gut microbiota composition in young rats [88], where SERT knock out rats
showed imbalanced microbial community dominated by members of the gut microbiota previously
reported to be associated with a state of intestinal inflammation, and brain disorders including multiple
depressive disorders [106,113–118]. Of note, the observed microbial imbalance was magnified when
young rats were exposed to another stimulus, maternal separation [88], implying that the absence or
domination of certain bacterial members in the gut of early-life stressed individuals may represent risk
factors for the development of depression during later life stages.
Gut produced serotonin has been the target of several antidepressants, such as fluoxetine,
which block its transport into the plasma via targeting SERT, thus named selective serotonin
reuptake inhibitors (SSRIs). Administration of these antidepressants has been also successfully
used as a treatment for gastrointestinal diseases, such as motility disorder and gastrointestinal
bleeding [92,119], confirming comorbidity of these disorders, but exert a puzzling effect on the
intestinal bacterial composition. Fluoxetine has an antimicrobial activity against Gram-positive
bacteria such as Staphylococcus and Enterococcus and some anaerobic bacteria such as Clostridium difficile
and Clostridium perfringens [3,120–122]. Similarly, Gram-negative bacteria such as Citrobacter spp.,
Pseudomonas aeruginosa, Klebsiella pneumoniae and Morganella morganii have been proven to be
susceptible to SSRIs [120,123]. Notably, most of these bacteria are key players in induction of
inflammation in the gut [99,100,103–108]. This suggests that through their antimicrobial activity,
antidepressants might restore a balanced composition of the gut microbiota, and immune response,
hence re-establish homeostasis at the gut–brain interphase. Deciphering the actual contribution of
the antimicrobial effects of antidepressants for treatment of depression as well as determining the
long-term consequences of these effects to gut microbiota composition and their implications to clinical
outcomes is crucial for the development of microbiota derived therapeutic alternatives [3,8,120,123].
Taken together, game-changing science is suggesting that depression is not only a result of
a deficiency of serotonin and other neurotransmitters in the brain, but could rather start in the
gut, via changing the microbiota composition through consumption of processed, nutrient poor
diet, which in turn, leads to a state of inflammation, imbalanced levels of neurotransmitters, and
eventually depression.
3.3. The Dual Effect of Gut Microbiota and Its Metabolites in Depression
Recently, changes in the composition of the gut microbiota have been associated with
depressive-like behavior in humans and animal models [124,125]. Decreased levels of bacterial genera
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Bifidobacterium and Lactobacillus and increased levels of Streptococcaceae, Clostridiales, Eubacteriaceae
and Ruminococcaceae, have been positively correlated with depressive symptoms [124,126]. Kelly et al.
have shown that fecal microbiota transplantation from depressed patients to microbiota-depleted
rats induced behavioral and physiological changes, leading to anxiety-like behaviors in the recipient
animals, as well as alterations in tryptophan metabolism [125]. This suggests that changes in gut
microbiota composition could play a causative role in the onset of depression.
Probiotic therapies have been applied in an attempt to correct for the possible absence of
microbiota species capable of exhibiting suitable drivers of a “healthy” behavior. For example, the
classical probiotics, Bifidobacteria and Lactobacilli, have been recently suggested as an alternative
treatment for anxiety and depressive-like behaviors. Oral administration of a combination of
Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 (Probio’Stick®, Lallemand, Montreal,
QC, Canada) for a period of one month, has been reported to improve depression, anxiety, and lower
the level of the stress hormone cortisol in humans (n = 26) [127]. A three-week consumption of a
probiotic-containing milk drink that contained Lactobacillus casei Shirota, showed improved mood in
healthy volunteers (n = 124) [128]. Similarly, when healthy male and female participants (n = 20) were
administered with, either a placebo product or a mixture of several probiotics strains of Bifidobacteria
and Lactobacilli over a period of 4 weeks, they exhibited substantially reduced reactivity to sad
mood compared to control group [129]. Another small (n = 12) placebo-controlled study involving
functional magnetic imaging has also demonstrated that a one-month consumption of a fermented food
containing Bifidobacterium animalis subsp. lactis, Streptococcus thermophilus, Lactobacillus bulgaricus, and
Lactococcus lactis subsp. lactis can influence brain activity as compared to baseline [130]. More recently,
Lactobacillus reuteri has been described to reduce despair like behavior in mice by inhibiting elevated
levels of IDO and reducing peripheral levels of kynurenine [131]. Whether the observed antidepressant
effect of probiotics is due to their modulation of an intestinal inflammatory state, restoration of
tryptophan metabolism, or reduction in serotonin turnover is still unclear.
Important to consider is indeed the influence of altered IDO activity and kynurenine pathway
metabolism induced by gut microbiota [132]. In the germ-free state, microbial colonization induced the
expression of genes encoding IDO, suggesting that gut microbiota activates this enzyme [17,96,132].
Moreover, other bacteria that flourish in an inflammatory environment, in particular Pseudomonas
genera, can catabolize tryptophan into kynurenine via tryptophan 2,3-dioxygenase, kynA and
kynurenine formamidase, kynB [133] (Figure 1D). Whether intestinal proinflammatory cytokines
or any other metabolites have similar effect on induction of kynA and kynB expression in this
bacterium, and subsequent increased levels of downstream metabolites, is still unknown. Additionally,
in Pseudomonas aeruginosa, kynurenine acts as the main precursor of the Pseudomonas quinolone signal,
a quorum-sensing signal that regulates numerous virulence genes in these bacteria [133]. This suggests
that shifting tryptophan metabolism towards kynurenine during inflammation might result in inducing
virulence in Pseudomonas, which in turn, causes imbalance in the microbial population, and disruption
in the kynurenine and serotonin signaling systems, eventually leading to a state of depression.
Besides the kynurenine and serotonin arms within tryptophan metabolism, indole represents
another important product in this metabolic pathway. Indole and its derivatives are exclusively
produced by gut bacterial metabolism of tryptophan, via the tryptophanase (tnaA) enzyme [111,134,135].
In their recent rodent study, Jaglin et al. suggested that human subjects, who carry microbiota
type dominated by species capable of overproducing indole may be more prone to develop anxiety
and mood disorders [136]. The authors mimicked this situation by injecting indole in the cecum
of conventional rats. The treated rats showed a dramatic decrease of motor activity, and higher
levels of the indole-derivatives oxindole and isatin were detected in the brain. When germ-free rats
were colonized with the indole-producing bacterial species E. coli to mimic a state of a chronic and
moderate overproduction of indole and compared their behavior with that observed in germ-free
counterparts mono-colonized with a mutant strain E. coli−∆tnaA, which is unable to produce indole,
only rats colonized with wild-type strain showed anxiety-like behavior suggesting that indole and its
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metabolites might play a role in developing depression [136]. This study implies a direct mechanism
by which the gut microbiota can influence the brain, and result in a state of depression, in this case via
the production of the neuro-suppressive indole-derivatives; oxindole and isatin, which are products of
gut epithelial or hepatic xenobiotic metabolizing enzymes (Figure 1D). However, another plausible
mechanism could be through activation of the vagal afferent fibers in the intestinal mucosa either
directly by indole or indirectly via secondary signals whose production could be triggered by indole.
Another indole derivative, indole pyruvic acid, was shown to normalize the level of corticosterone in
rodent model of depression and this effect was suggested to be due to the production of kynurenic
acid in the brain [137]. Altogether, further studies are warranted for a comprehensive understanding
of the mechanisms governing the beneficial or detrimental effects of gut microbiota and its metabolites
on mood and behavior.
4. Conclusions and Future Perspectives
Given the mounting evidence over the past five years that microbiota play a key role at the
gut–brain interphase shows a need to reveal the mechanisms that underpin this interaction in order to
close the gap between therapeutic strategies and fundamental science. That the metabolites of the gut
microbiota is evident to have a substantial effect on the regulation of immune response, tryptophan
metabolism, and serotonin production, a diet characterized by nutrient-poor, energy-dense processed
foods can well explain the strong link between depression and this multifaceted crosstalk. Restoring
the gut microbiota composition via nutritional interventions could be an indirect strategic tool to treat
depression. The use of selective dietary microbial growth substrates could be as beneficial but may
result in long-lasting changes of the microbiome compared to the application of probiotic therapies.
Achieving a better understanding of the role of the complex triggers of depression requires further
development of analytical approaches, including, metabolomics, to allow unraveling the metabolic
dialogue between the microbiota and gut–brain axis. Equally important is the development of reliable
models to decipher the complex interactions between the gut microbiota and its products, disruptions
in immune response and dietary metabolism, all of which ultimately affect brain functionality, mood
and behavior. The use of reductionist animal models has been very helpful in identifying underlying
mechanisms in the host–microbe cross talk. However, it is increasingly clear that animal models
fall short in translation to humans. Data acquired from large longitudinal human cohorts followed
over long period of time, is essential to understand the real-world complexity of these interactions.
Currently, there is an exponential growth of large bio-banks holding vast amounts of information
about the same individual [138–140]. If combined with the state-of-art technologies including bacterial
culturomics and individualized organs-on-chips to further understand the underlying causalities and
mechanisms, only then we can bridge the gap between basic science and clinical practice and make
major advances in personalized medicine.
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question marks indicate missing links in this multi-faceted crosstalk. Dotted lines depict effects on 
gut motility. Abbreviations: 5-HIAA = 5-hydroxyindoleacetic acid; 5-HT = serotonin; 5-HTx = 
serotonin receptors; AA = anthranilic acid; BDNF = brain-derived neurotrophic factor; CVOs = 
t icr i ta re otely influences brain and depre sion. Potential routes by which the gut
r the co orbidity of gut inflammation, disruption in tryptophan metabolism,
. (A) Signaling mechanisms in the brain stimulated by infla matory
in the gut; (B) molecular mechanism by which the enteric nervous system affects gut motility
and tr ptophan metabolism during intestinal inflammation; (C) possible alterations of serotonin
ignaling in lami a propr a resulting in gut hypermobility and nflammatory resp nse; (D) influence
of th gut microbiota and its secreted compounds on disruption on ryptophan met bolism and gut
inflammation. Red triangles epresent decr ase /increased production or expression. Red question
marks i dicate missing link i this multi-faceted crosstalk. D tted lines d pict effects on gut motility.
Abbreviat ons: 5-HIAA = 5-hydroxyindoleacetic acid; 5-HT = serotonin; 5-HTx = ser to in receptors;
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AA = anthranilic acid; BDNF = brain-derived neurotrophic factor; CVOs = circumventricular
organs; EC cell = enterochromaffin cell; HPA axis = hypothalamus-pituitary adrenal axis;
IDO = indoleamine-2,3-dioxygenase; IFN-γ = interferon γ; IPAN = intrinsic primary afferent
neuron; KMO = kynurenine-3-monooxygenase; KYN = kynurenine; KYNA = kynurenic acid;
MAO = monoamine oxidase; NMDA receptors = N-methyl-D-aspartate receptors; QA = quinolinic
acid; SCFAs = short-chain fatty acids; SERT = serotonin transporter; TNF-α = tumor necrosis factor
α; TPH1 = tryptophan hydroxylase; TRP = tryptophan; f5OHKYM = formyl-5-hydroxykynuramine;
kynA = tryptophan-2,3-dioxygenase from Pseudomonas spp.; kynB = kynurenine formamidase from
Pseudomonas spp.; tnaA = tryptophanase.
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